Novo Nordisk A/S Common Stock (NVO)

The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's decision on semaglutide shortage.

Steve Benz, legal and US general counsel of Novo Nordisk, said the company is “pleased” that the court rejected the compounders' attempts to “undermine” the FDA's decision that the shortages of Wegovy and Ozempic have been resolved.

Ignore the noise. Novo Nordisk stock is a bargain.

Viking Therapeutics stock is trying to push higher as investors attempt to sort out a report that delivered no real news that investors hadn’t already heard.

Take a deep dive into Eli Lilly's latest clinical GLP-1 results that sent shares soaring. The company has a big opportunity to serve needle-phobic patients.

The Trump Administration is reportedly mulling over a policy to match U.S. drug prices with those in other developed nations.

The competitive landscape for GLP-1 agonist weight loss drugs has undergone a significant shake-up.

Eli Lilly gains analyst support after Phase 3 success. Bullish forecasts for obesity dominance and key earnings are set for May 1.

Novo Nordisk has a GLP-1 Ozempic pill. That's both good and bad news for Novo Nordisk stock.

Reports suggest Novo Nordisk has asked the FDA to approve its oral semaglutide, two years after reporting a Phase 3 win.

The request reportedly came two years after a Phase 3 study of Rybelsus, an oral formulation of semaglutide, which showed successful results.

Healthcare sector sees volatility due to UnitedHealth's earnings disappointment, but ETFs like XLV, IHE, and XPH still show resilience and pockets of strength.

Wall Street experienced a resurgence in risk appetite on Thursday as optimism grew around trade negotiations.

Lilly's weight-loss drug trial shows promising results, propelling stock up 14.36%. Goldman Sachs predicts potential $23.5B in sales by 2035.

Analyst downgrades Novo Nordisk, citing Eli Lilly's rising dominance and weak competitive outlook for 2025.